An interventional study of Replenish protein group and Standard protein group in Critical Illness and Nutrition Disorders, sponsored by King Abdullah International Medical Research Center. Recruiting at 2 sites in Saudi Arabia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by King Abdullah International Medical Research Center · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The investigator will investigate the effect of supplemental enteral protein (1.2 g/kg/day) added to standard formula to achieve high amount of enteral protein (range 2-2.4 g/kg/day) given from ICU day 5 until ICU discharge up to ICU day 90 as compared to no supplemental enteral protein to achieve moderate amount enteral protein (0.8-1.2 g/kg/day), given in conjunction with similar amounts of stepwise caloric administration in the two groups on all-cause 90-day mortality.
The REPLENISH is a multicentric, international, open label, randomized controlled trial which will enroll subjects in intensive care unit. Patients will be randomized on day 4 of ICU admission. Until ICU day 4, protein requirement will be provided according to the local practice as long as no intravenous amino acids are given and the average protein intake in the first 4 days does not exceed 0.8 g/kg/day. On ICU day 4, patients will be randomized to one of the two treatment groups: one with standard prescription without supplemental proteins (maximum1.2 g/kg/day) from the primary polymeric formula and another group will receive the standard amount of proteins (maximum 1.2 g/kg/day) from the primary polymeric formula AND supplemental protein at 1.2 g/kg/day.
Randomization will be stratified by suspected COVID-19 and then by site and the use of renal replacement therapy at the time of randomization (intermittent hemodialysis or continuous renal replacement therapy.
233 studies on the registry are indexed under Nutrition Disorders; 26 are open to participants now.
This study's planned enrollment of 2,502 is above the median of 105 across 169 interventional studies indexed under Nutrition Disorders.
Browse Nutrition Disorders studies →King Abdullah International Medical Research Center is the lead sponsor of 46 studies on the registry; 6 are open to participants now.
Compared within Nutrition Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria(on ICU calendar day 4 or the morning of day 5)
Exclusion Criteria:
The subjects randomized to this group will receive the standard amount of proteins (maximum 1.2 g/kg/day) from the primary polymeric formula AND supplemental protein at 1.2 g/kg/day
Other: Replenish protein group
The subjects randomized to this group will receive standard prescription without supplemental proteins (maximum1.2 g/kg/day) from the primary polymeric formula. No supplemental protein will be allowed
Other: Standard protein group
For patients with Body mass index(BMI) \<30, use pre-ICU actual body weight(BW) for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
For patients with BMI \<30, use pre-ICU actual BW for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
90 day-all cause mortality
Mortality 90 days post randomization
Time frame: 90 days
Days alive at day 90 without life support
use of vasopressor/inotropic support, invasive mechanical ventilation and/or renal replacement therapy
Time frame: 90 days
Days alive and out of hospital at day 90
90 day survival after randomization
Time frame: 90 days
Bacteremia until 2 days of ICU stay
Any symptoms of bacteremia
Time frame: until 2 days post ICU.
New or progression of Skin Pressure Ulcers
anytime during ICU stay
Time frame: ICU stay
Functional assessment at day 90
SARC-F screen for sarcopenia and EuroQoL
Time frame: Day 90
Safety outcomes during ICU stay
New episode of stage 2 or higher AKI by KDIGO criteria; 2. Pneumonia defined as episodes of newly confirmed pneumonia according to the modified CDC criteria; 3. Grade IV Acute Gastrointestinal injury (AGI)
Time frame: ICU stay
Minor safety outcomes during ICU stay
Feeding tolerance; Diarrhoea; Refeeding syndrome
Time frame: ICU stay
Plan to share: No
Started Sep 2020 (actual). Primary completion is estimated for Nov 2025, 62 months after the start.
Of 54 non-industry interventional studies with no phase under Nutrition Disorders, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 57. This study's planned 62 months is above that.
Counting every sponsor, half of 56 studies reached it within 22 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
King Abdullah International Medical Research Center